Opin vísindi

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis : a combined analysis of multiple studies

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis : a combined analysis of multiple studies


Title: Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis : a combined analysis of multiple studies
Author: Curtis, Jeffrey R.
Weinblatt, Michael E.
Shadick, Nancy A.
Brahe, Cecilie H.
Østergaard, Mikkel
Hetland, Merete Lund   orcid.org/0000-0003-4229-6818
Sævarsdóttir, Sædís
Horton, Megan
Mabey, Brent
Flake, Darl D.
... 3 more authors Show all authors
Date: 2021-01-04
Language: English
Scope: 1
Department: Faculty of Medicine
Series: Arthritis Research and Therapy; 23(1)
ISSN: 1478-6354
DOI: https://doi.org/10.1186/s13075-020-02389-4
Subject: Röntgenrannsóknir; Iktsýki; Biomarker; Disease activity; Radiographic progression; Rheumatoid arthritis; Risk prediction; Severity of Illness Index; Prognosis; Humans; Biomarkers; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/diagnostic imaging; Disease Progression; Rheumatology; Immunology and Allergy; Immunology
URI: https://hdl.handle.net/20.500.11815/2874

Show full item record

Citation:

Curtis , J R , Weinblatt , M E , Shadick , N A , Brahe , C H , Østergaard , M , Hetland , M L , Sævarsdóttir , S , Horton , M , Mabey , B , Flake , D D , Ben-Shachar , R , Sasso , E H & Huizinga , T W 2021 , ' Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis : a combined analysis of multiple studies ' , Arthritis Research and Therapy , vol. 23 , no. 1 , 1 , pp. 1 . https://doi.org/10.1186/s13075-020-02389-4

Abstract:

BACKGROUND: The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression. We now extend these findings with additional cohorts to further validate the adjusted MBDA score as a predictor of radiographic progression risk and compare its performance with that of other risk factors. METHODS: Four cohorts were analyzed: the BRASS and Leiden registries and the OPERA and SWEFOT studies (total N = 953). Treatments included conventional DMARDs and anti-TNFs. Associations of radiographic progression (ΔTSS) per year with the adjusted MBDA score, seropositivity, and clinical measures were evaluated using linear and logistic regression. The adjusted MBDA score was (1) validated in Leiden and SWEFOT, (2) compared with other measures in all four cohorts, and (3) used to generate curves for predicting risk of radiographic progression. RESULTS: Univariable and bivariable analyses validated the adjusted MBDA score and found it to be the strongest, independent predicator of radiographic progression (ΔTSS > 5) compared with seropositivity (rheumatoid factor and/or anti-CCP), baseline TSS, DAS28-CRP, CRP SJC, or CDAI. Neither DAS28-CRP, CDAI, SJC, nor CRP added significant information to the adjusted MBDA score as a predictor, and the frequency of radiographic progression agreed with the adjusted MBDA score when it was discordant with these measures. The rate of progression (ΔTSS > 5) increased from < 2% in the low (1-29) adjusted MBDA category to 16% in the high (45-100) category. A modeled risk curve indicated that risk increased continuously, exceeding 40% for the highest adjusted MBDA scores. CONCLUSION: The adjusted MBDA score was validated as an RA disease activity measure that is prognostic for radiographic progression. The adjusted MBDA score was a stronger predictor of radiographic progression than conventional risk factors, including seropositivity, and its prognostic ability was not significantly improved by the addition of DAS28-CRP, CRP, SJC, or CDAI.

Description:

This work was supported by Myriad Genetics, Inc. Publisher Copyright: © 2021, The Author(s).

Files in this item

This item appears in the following Collection(s)